San Diego-based Viking Therapeutics marked itself as a serious competitor within the weight loss drug current market in February soon after revealing promising info from the mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when specified as being a weekly injection and in March the